You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • THU0369 Secukinumab 150mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from phase iii trial, measure 2

Alerts

Article menu

Download PDFPDF

Poster Presentations
Spondyloarthritis - treatment
THU0369 Secukinumab 150mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from phase iii trial, measure 2
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address